Jafron Biomedical Co Ltd (300529) — Tangible Net Worth Ratio
Jafron Biomedical Co Ltd (300529) has a Tangible Net Worth Ratio of 97.3% as of March 2026. This metric is calculated by deducting intangible assets (CN¥99.76 Million) from net assets (CN¥3.70 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300529 book value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Jafron Biomedical Co Ltd Tangible Net Worth Ratio (2011–2025)
This chart shows how Jafron Biomedical Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 97.3%, reflecting net assets of CN¥3.70 Billion with intangible assets of CN¥99.76 Million CNY. Also explore Jafron Biomedical Co Ltd (300529) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Jafron Biomedical Co Ltd (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Jafron Biomedical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Jafron Biomedical Co Ltd stock valuation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 97.1% | CN¥3.47 Billion | CN¥100.66 Million | CN¥5.41 Billion | ▲ +0.0 pp |
| 2024 | 97.1% | CN¥3.33 Billion | CN¥97.75 Million | CN¥5.38 Billion | ▲ +0.3 pp |
| 2023 | 96.8% | CN¥3.15 Billion | CN¥100.37 Million | CN¥5.54 Billion | ▼ -0.4 pp |
| 2022 | 97.2% | CN¥3.59 Billion | CN¥100.43 Million | CN¥5.41 Billion | ▲ +0.2 pp |
| 2021 | 97.0% | CN¥3.38 Billion | CN¥101.31 Million | CN¥4.81 Billion | ▲ +0.2 pp |
| 2020 | 96.8% | CN¥2.83 Billion | CN¥89.89 Million | CN¥3.22 Billion | ▼ -1.0 pp |
| 2019 | 97.8% | CN¥2.17 Billion | CN¥48.05 Million | CN¥2.49 Billion | ▲ +0.5 pp |
| 2018 | 97.3% | CN¥1.72 Billion | CN¥46.59 Million | CN¥2.05 Billion | ▼ -0.5 pp |
| 2017 | 97.8% | CN¥1.39 Billion | CN¥30.91 Million | CN¥1.70 Billion | ▼ -0.8 pp |
| 2016 | 98.6% | CN¥1.18 Billion | CN¥17.14 Million | CN¥1.30 Billion | ▲ +1.7 pp |
| 2015 | 96.9% | CN¥564.06 Million | CN¥17.47 Million | CN¥688.67 Million | ▲ +0.6 pp |
| 2014 | 96.3% | CN¥452.42 Million | CN¥16.72 Million | CN¥539.01 Million | ▲ +0.5 pp |
| 2013 | 95.8% | CN¥380.12 Million | CN¥16.14 Million | CN¥461.73 Million | ▲ +1.4 pp |
| 2012 | 94.3% | CN¥290.84 Million | CN¥16.47 Million | CN¥341.58 Million | ▲ +2.0 pp |
| 2011 | 92.3% | CN¥215.57 Million | CN¥16.59 Million | CN¥246.24 Million | — |